Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 3/20 | 0.37 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232011 | 1.00 | AKR1C3 (0.45) | AKR1C3GRM1PANK3CHRM1SLC6A7 | |
| SCHEMBL30281529 | 0.83 | GPR119 (0.51) | — | |
| SCHEMBL31070375 | 0.83 | GPR119 (0.51) | — | |
| SCHEMBL25666892 | 0.83 | GPR119 (0.51) | — | |
| SCHEMBL31070380 | 0.83 | GPR119 (0.51) | — | |
| SCHEMBL14913148 | 0.83 | GRM1 (0.40) | GRM1CHRM1SLC6A7SMO | |
| SCHEMBL16112455 | 0.82 | AKR1C3 (0.42) | AKR1C3PANK3CHRM1KDM4EMAPT | |
| SCHEMBL18152253 | 0.82 | SLC6A7 (0.49) | GRM1PANK3SLC6A7SMO | |
| SCHEMBL16822 | 0.82 | SLC6A7 (0.49) | GRM1PANK3SLC6A7SMO | |
| SCHEMBL1735011 | 0.81 | SGPL1 (0.51) | KDM4EMAPTPOLBSMOSGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589467-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589466-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| CN-115485278-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2022-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | AKR1C3 3809/4885GRM1 3192/4885PANK3 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.